ATE441409T1 - Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber - Google Patents

Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber

Info

Publication number: ATE441409T1
Authority: AT; Austria
Prior art keywords: amino acid; liver; low; functional disorders; level
Prior art date: 2001-03-15

Application number

AT02705258T

Other languages

English (en)

Inventor

Takashi Abe

Masato Saitou

Original Assignee

Riken

Meiji Dairies Corp

Takashi Abe

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-15

Filing date

2002-03-15

Publication date

2009-09-15

2002-03-15 Application filed by Riken, Meiji Dairies Corp, Takashi Abe filed Critical Riken

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE441409T1 publication Critical patent/ATE441409T1/de

Links

150000001413 amino acids Chemical class 0.000 title abstract 7
210000004185 liver Anatomy 0.000 title abstract 6
239000000203 mixture Substances 0.000 title abstract 6
230000007257 malfunction Effects 0.000 title 1
229940024606 amino acid Drugs 0.000 abstract 6
235000001014 amino acid Nutrition 0.000 abstract 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
239000006035 Tryptophane Substances 0.000 abstract 2
239000008280 blood Substances 0.000 abstract 2
210000004369 blood Anatomy 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
229960004799 tryptophan Drugs 0.000 abstract 2
235000017103 tryptophane Nutrition 0.000 abstract 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
239000004475 Arginine Substances 0.000 abstract 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
239000004473 Threonine Substances 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
231100000570 acute poisoning Toxicity 0.000 abstract 1
235000004279 alanine Nutrition 0.000 abstract 1
229960003767 alanine Drugs 0.000 abstract 1
235000009697 arginine Nutrition 0.000 abstract 1
229960003121 arginine Drugs 0.000 abstract 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
235000003704 aspartic acid Nutrition 0.000 abstract 1
229960005261 aspartic acid Drugs 0.000 abstract 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
235000013922 glutamic acid Nutrition 0.000 abstract 1
229960002989 glutamic acid Drugs 0.000 abstract 1
239000004220 glutamic acid Substances 0.000 abstract 1
229960002449 glycine Drugs 0.000 abstract 1
235000014304 histidine Nutrition 0.000 abstract 1
229960002885 histidine Drugs 0.000 abstract 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
235000014705 isoleucine Nutrition 0.000 abstract 1
229960000310 isoleucine Drugs 0.000 abstract 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
235000005772 leucine Nutrition 0.000 abstract 1
229960003136 leucine Drugs 0.000 abstract 1
235000018977 lysine Nutrition 0.000 abstract 1
229960003646 lysine Drugs 0.000 abstract 1
235000006109 methionine Nutrition 0.000 abstract 1
229930182817 methionine Natural products 0.000 abstract 1
229960004452 methionine Drugs 0.000 abstract 1
235000008729 phenylalanine Nutrition 0.000 abstract 1
229960005190 phenylalanine Drugs 0.000 abstract 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
229960002429 proline Drugs 0.000 abstract 1
235000004400 serine Nutrition 0.000 abstract 1
229960001153 serine Drugs 0.000 abstract 1
229960002898 threonine Drugs 0.000 abstract 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
235000002374 tyrosine Nutrition 0.000 abstract 1
229960004441 tyrosine Drugs 0.000 abstract 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
235000014393 valine Nutrition 0.000 abstract 1
229960004295 valine Drugs 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Addiction (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Meat, Egg Or Seafood Products (AREA)

AT02705258T 2001-03-15 2002-03-15 Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber ATE441409T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001074964		2001-03-15
PCT/JP2002/002500 WO2002074302A1 (fr)	2001-03-15	2002-03-15	Compositions d'acides amines utilisees pour ameliorer l'insuffisance hepatique

Publications (1)

Publication Number	Publication Date
ATE441409T1 true ATE441409T1 (de)	2009-09-15

Family

ID=18932127

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02705258T ATE441409T1 (de)	2001-03-15	2002-03-15	Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber

Country Status (7)

Country	Link
US (1)	US20040192751A1 (de)
EP (1)	EP1374863B1 (de)
JP (1)	JPWO2002074302A1 (de)
AT (1)	ATE441409T1 (de)
DE (1)	DE60233558D1 (de)
TW (1)	TWI309162B (de)
WO (1)	WO2002074302A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2319581T1 (sl)	2004-11-26	2015-10-30	Ucl Business Plc	Pripravki, ki obsegajo ornitin in fenilacetat ali fenilbutirat za zdravljenje hepatične encefalopatije
JP5188181B2 (ja) *	2005-08-25	2013-04-24	協和発酵バイオ株式会社	血中アルコール濃度上昇抑制用組成物
NO2413924T3 (de)	2009-04-03	2018-02-24
BRPI1012956A8 (pt)	2009-06-08	2021-11-03	Ocera Therapeutics Inc	Usos da l-ornitina e de pelo menos um de fenilacetato e fenilbutirato
KR101213825B1 (ko) *	2010-07-16	2012-12-18	서울대학교산학협력단	세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물
JP6087284B2 (ja)	2010-10-06	2017-03-01	オセラセラピューティクス，インコーポレイテッド	Ｌ−オルニチンフェニルアセテートを製造するための方法
CN107206021B (zh)	2014-11-24	2021-09-03	Ucl商业有限公司	使用降氨疗法治疗与肝星状细胞激活相关的疾病
JP2016132622A (ja) *	2015-01-16	2016-07-25	イーエヌ大塚製薬株式会社	敗血症治療又は予防用栄養組成物
AU2016308641B2 (en)	2015-08-18	2022-02-03	Ocera Therapeutics, Inc.	Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
JOP20190146A1 (ar)	2016-12-19	2019-06-18	Axcella Health Inc	تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
AU2018258250A1 (en) *	2017-04-25	2019-12-12	Almeda Labs Llc	Amino acid formulations for pancreatic viability
AU2018266357B2 (en)	2017-05-11	2022-12-08	Ocera Therapeutics, Inc.	Processes of making L-ornithine phenylacetate
CN111295187A (zh) *	2017-08-14	2020-06-16	胺细拉健康公司	用于治疗肝脏疾病的氨基酸组合物
US11173143B2 (en)	2017-08-30	2021-11-16	Asahi Group Holdings, Ltd.	Composition for decreasing serum uric acid level
JP2021066662A (ja) *	2018-02-15	2021-04-30	国立大学法人東北大学	肝脂肪低減剤
CN112839643A (zh)	2018-06-20	2021-05-25	胺细拉健康公司	用于治疗肌肉中脂肪浸润的组合物及方法
US20190388377A1 (en) *	2018-06-20	2019-12-26	Axcella Health Inc.	Compositions and methods for the treatment of liver diseases and disorders
CN111265476B (zh) *	2020-04-08	2021-05-04	河北科星药业有限公司	一种畜用复方氨基酸注射液的制备方法
CN111329836B (zh) *	2020-04-08	2021-04-30	河北科星药业有限公司	畜用复方氨基酸注射液的制备方法
CN111358753A (zh) *	2020-04-08	2020-07-03	河北科星药业有限公司	畜用复方氨基酸注射液及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3950529A (en) *	1975-02-03	1976-04-13	Massachusetts General Hospital	Amino acid formulations for patients with liver disease and method of using same
JPS568312A (en) *	1979-07-03	1981-01-28	Otsuka Pharmaceut Factory Inc	Amino acid pharmaceutical preparation
JPS6354320A (ja) *	1986-08-26	1988-03-08	Ajinomoto Co Inc	抗アルコ−ル症組成物
JP2518692B2 (ja) *	1989-06-14	1996-07-24	理化学研究所	筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤
US5266685A (en) *	1992-05-05	1993-11-30	Grain Processing Corporation	Non-bitter protein hydrolyzates
JPH0624976A (ja) *	1992-07-10	1994-02-01	Rikagaku Kenkyusho	輸液用組成物
US5981472A (en) *	1997-02-21	1999-11-09	Dx/Ibr Corporation	Methods for treating diseases
JPH11302164A (ja) *	1998-04-20	1999-11-02	Shimizu Pharmaceutical Co Ltd	アミノ酸組成物
US6506552B2 (en) *	1998-08-24	2003-01-14	Meiji Dairies Corporation	Amino acid-trehalose composition
JP2000072669A (ja) *	1998-08-24	2000-03-07	Inst Of Physical & Chemical Res	アミノ酸・糖組成物

2002
- 2002-03-15 DE DE60233558T patent/DE60233558D1/de not_active Expired - Fee Related
- 2002-03-15 WO PCT/JP2002/002500 patent/WO2002074302A1/ja active Application Filing
- 2002-03-15 EP EP02705258A patent/EP1374863B1/de not_active Expired - Lifetime
- 2002-03-15 TW TW091104902A patent/TWI309162B/zh not_active IP Right Cessation
- 2002-03-15 AT AT02705258T patent/ATE441409T1/de not_active IP Right Cessation
- 2002-03-15 JP JP2002573010A patent/JPWO2002074302A1/ja active Pending
- 2002-03-15 US US10/471,850 patent/US20040192751A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2002074302A1 (fr)	2002-09-26
EP1374863B1 (de)	2009-09-02
JPWO2002074302A1 (ja)	2005-07-14
TWI309162B (en)	2009-05-01
EP1374863A4 (de)	2005-01-12
US20040192751A1 (en)	2004-09-30
EP1374863A1 (de)	2004-01-02
DE60233558D1 (de)	2009-10-15

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE441409T1 (de)	2009-09-15	Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
AR051512A1 (es)	2007-01-17	Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3"
BR0313970A (pt)	2005-09-06	Composições pesticidas contendo ácidos dicarboxìlicos
AR061054A1 (es)	2008-07-30	Compuestos acidos de glicerilo y glicol
ES2113606T3 (es)	1998-05-01	Cetonas peptidicas como inhibidores de la enzima convertidora de la interleuquina-1beta.
DK1755634T3 (da)	2009-02-16	Oligopeptider til formindskelse af forhöjet blodurinstofkoncentration
WO2008089491A3 (en)	2008-11-27	Modifications of peptide compositions to increase stability and delivery efficiency
AR029851A1 (es)	2003-07-16	Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
DK1478394T3 (da)	2008-10-13	Stabiliseret TNFR-Fc formulation med arginin
ECSP088962A (es)	2009-01-30	Nuevos herbicidas
DK1243263T3 (da)	2003-03-17	Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
BRPI0415121A (pt)	2006-11-28	material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
BRPI0515118A (pt)	2008-07-01	conjugados de hormÈnio do crescimento humano com polietileno glicol
DK1706457T3 (da)	2012-05-21	Fremstilling af 3-hydroxypropionsyre ved anvendelse af beta-alanin/pyruvataminotransferase
WO2008039415A3 (en)	2008-11-13	Analogs of ghrelin substituted at the n-terminal
DE502007000371D1 (de)	2009-03-05	Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung
CY1115918T1 (el)	2017-01-25	Συνθεσεις βασιζομενες επι διακλαδισμενης αλυσου αμινοξεων για βελτιωση της μυοκαρδιακης κοιλιακης λειτουργιας σε ασθενεις που υποφερουν απο διαβητη
WO2005077103A3 (en)	2009-04-09	Compositions and methods for modification and prevention of sars coronavirus infectivity
CY1112992T1 (el)	2016-04-13	Μεσο καλλιεργειας χωρις ορο για την παρασκευη ανασυνδυασμενων γοναδοτροπινων
DK1273299T3 (da)	2006-02-06	Minoxidilinindeholdende praparater
SE0002202D0 (sv)	2000-06-13	New peptides
WO2005034932A3 (en)	2005-06-30	Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function
BR0109846A (pt)	2003-06-03	Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto
ATE322503T1 (de)	2006-04-15	Gefrierschutzprotein
EP1908492A4 (de)	2008-12-10	Metabotroper glutamat-rezeptor-aktivator